Leading edge biological long-term treatment of AIDS original new drug ibove Taiwang takes the lead in the market

There are 35.3 million people infected with HIV, 2.3 million new infections and 1.6 million people died of AIDS This shocking set of figures tells us that AIDS has become the biggest threat to human health It is understood that HIV is easy to produce resistance to a single drug, so the current treatment of AIDS is "cocktail" therapy, several drugs are mixed together to eat a large number After a period of treatment, patients will have drug resistance and need new drugs to control and kill the virus again Without new drugs, these people would be left with no cure Currently, most of the drugs used to treat AIDS in China are generic drugs with expired foreign patents, with poor efficacy and large side effects The anti AIDS drug "ibovetai" developed by Nanjing frontier Biotechnology Co., Ltd is a long-term drug It will change the frequency of drug use to one injection a week, and it is also the first long-term drug to treat AIDS in the world "Phase III clinical trial is the last step before going to the market In this clinical trial, many patients actively request to participate in the efficacy trial After using it, they feel very good and hope to continue to receive treatment " Speaking of the new drugs developed, Dr Wang Yong, deputy general manager of Nanjing frontier Biotechnology Co., Ltd., said excitedly It is reported that there are three new drugs for AIDS treatment in the world now under research and development The R & D center of Janssen Ireland and jsk are still in phase I of Linchuang, while the "ibovetai" of Nanjing frontier Biotechnology Co., Ltd has entered the late phase of phase III of Linchuang, and is expected to be launched in the summer of 2016.